WallStSmart

AstraZeneca PLC (AZN)vsCommunity Health Systems Inc (CYH)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

AstraZeneca PLC generates 392% more annual revenue ($60.44B vs $12.29B). AZN leads profitability with a 17.2% profit margin vs 3.8%. AZN appears more attractively valued with a PEG of 1.39. AZN earns a higher WallStSmart Score of 64/100 (C+).

AZN

Buy

64

out of 100

Grade: C+

Growth: 6.0Profit: 8.5Value: 6.0Quality: 5.0
Piotroski: 6/9Altman Z: 1.48

CYH

Hold

45

out of 100

Grade: D+

Growth: 2.7Profit: 5.0Value: 8.0Quality: 6.0
Piotroski: 5/9Altman Z: 1.06
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AZNUndervalued (+8.2%)

Margin of Safety

+8.2%

Fair Value

$194.77

Current Price

$185.95

$8.82 discount

UndervaluedFair: $194.77Overvalued
CYHUndervalued (+87.2%)

Margin of Safety

+87.2%

Fair Value

$26.37

Current Price

$2.74

$23.63 discount

UndervaluedFair: $26.37Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AZN4 strengths · Avg: 8.8/10
Market CapQuality
$282.69B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
21.9%9/10

Every $100 of equity generates 22 in profit

Operating MarginProfitability
27.9%8/10

Strong operational efficiency at 27.9%

Free Cash FlowQuality
$1.82B8/10

Generating 1.8B in free cash flow

CYH2 strengths · Avg: 10.0/10
P/E RatioValuation
0.9x10/10

Attractively priced relative to earnings

Debt/EquityHealth
-7.4010/10

Conservative balance sheet, low leverage

Areas to Watch

AZN2 concerns · Avg: 3.0/10
P/E RatioValuation
27.5x4/10

Moderate valuation

Altman Z-ScoreHealth
1.482/10

Distress zone — elevated risk

CYH4 concerns · Avg: 3.3/10
PEG RatioValuation
2.384/10

Expensive relative to growth rate

Market CapQuality
$422.75M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Profit MarginProfitability
3.8%3/10

3.8% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : AZN

The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.

Bull Case : CYH

The strongest argument for CYH centers on P/E Ratio, Debt/Equity.

Bear Case : AZN

The primary concerns for AZN are P/E Ratio, Altman Z-Score.

Bear Case : CYH

The primary concerns for CYH are PEG Ratio, Market Cap, Return on Equity. Thin 3.8% margins leave little buffer for downturns.

Key Dynamics to Monitor

AZN profiles as a mature stock while CYH is a value play — different risk/reward profiles.

CYH carries more volatility with a beta of 1.86 — expect wider price swings.

AZN is growing revenue faster at 12.5% — sustainability is the question.

AZN generates stronger free cash flow (1.8B), providing more financial flexibility.

Bottom Line

AZN scores higher overall (64/100 vs 45/100), backed by strong 17.2% margins and 12.5% revenue growth. CYH offers better value entry with a 87.2% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

AstraZeneca PLC

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.

Community Health Systems Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Community Health Systems, Inc. owns, leases and operates general acute care hospitals in the United States. The company is headquartered in Franklin, Tennessee.

Want to dig deeper into these stocks?